A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Phase 2 Terminated 141 enrolled Dompé Farmaceutici S.p.A

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.

Timeline

Start: 2021-01-12
Primary completion: 2025-03-31
Completion: 2025-10-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ladarixin	Unknown	400 mg	Oral

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Summary

Timeline

Drugs

Indications